PAHC Stock Cash Flow Statements

Phibro Animal Health Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Free Cash Flow

Capital Expenditure

Phibro Animal Health Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2006-03-31	2005-12-31	2005-09-30


operating activities
net income	17,224,000	752,000	11,498,000	7,487,000	17,121,000	5,642,000	8,802,000	22,119,000
adjustments to reconcile net income to
net cash from operating activities:
depreciation and amortization	12,411,000	9,201,000	8,574,000	8,405,000	7,843,000	8,164,000	7,157,000	6,917,000
amortization of debt issuance costs	572,000	260,000	213,000	148,000	171,000
deferred income taxes	8,362,000	-5,236,000	-3,073,000	-686,000	-2,201,000	9,404,000	-1,847,000	-1,624,000
foreign currency losses (gains)
acquisition-related items	2,337,000	-512,000		238,000
non-cash impairment charges	0
pension settlement cost		0
brazil employment taxes		0
stock-based compensation		179,000			0	565,000	565,000
other	-476,000	-5,963,000	1,535,000	35,000	1,455,000	198,000	502,000	794,000
changes in operating assets and liabilities, net of business acquisition:
accounts receivable	-25,957,000	-11,723,000	-9,650,000	-12,810,000	-9,799,000	24,704,000	-5,755,000	-12,196,000
inventories	-6,161,000	8,532,000	19,236,000	-16,451,000	-4,407,000	-19,514,000	-7,511,000	-2,563,000
other current assets	-8,634,000	7,603,000	62,000	75,000	-5,377,000	-9,296,000	-3,062,000	1,901,000
other assets	-2,237,000	3,298,000	1,067,000	643,000	-879,000	-752,000	-152,000	-225,000
accounts payable	2,619,000	3,901,000	-3,112,000	6,397,000	3,927,000	-3,513,000	7,717,000	-4,338,000
accrued expenses and other liabilities	26,116,000	9,284,000	-738,000	-591,000	-2,359,000	-5,816,000	9,852,000	-1,907,000
net cash from operating activities	21,272,000			1,574,000	3,070,000
investing activities
purchases of short-term investments	-4,000,000	0	0	-10,000,000	-24,000,000	-25,000,000	-6,000,000	-37,000,000
maturities of short-term investments	5,000,000	4,523,000	0	15,100,000	25,000,000	25,000,000	31,000,000
capital expenditures	-13,142,000	-13,072,000	-10,891,000	-11,890,000	-7,094,000	-10,076,000	-10,117,000	-5,529,000		-6,628,000	-2,217,000	-2,399,000
free cash flows	8,130,000			-10,316,000	-4,024,000
business acquisition, net of cash acquired	5,349,000	0
net cash used by investing activities	-7,034,000	-9,111,000	-10,282,000	-9,540,000	-7,190,000
financing activities
revolving credit facility borrowings	53,000,000	121,000,000	35,000,000	82,000,000	182,500,000	49,000,000	56,000,000	59,130,000
revolving credit facility repayments	-58,000,000	-110,000,000	-87,000,000	-61,000,000	-263,500,000	-26,000,000	-56,000,000	-54,630,000
proceeds from long-term debt	0		50,000,000									55,000
payments of long-term debt	-4,061,000	-6,980,000	-3,855,000									-717,000
debt issuance costs	0		-833,000
proceeds from insurance premium financing and other short-term debt		5,899,000
payments of insurance premium financing and other short-term debt		-3,271,000
dividends paid	-4,864,000	-4,861,000	-4,861,000	-4,861,000	-4,861,000	-4,855,000	-4,854,000	-4,036,000
net cash provided (used) by financing activities	-7,766,000			12,389,000	4,637,000	14,985,000		-711,000
effect of exchange rate changes on cash	1,213,000	-717,000	419,000	-923,000	592,000	266,000	74,000	-762,000		90,000	-21,000	31,000
net increase in cash and cash equivalents	7,685,000	20,388,000	4,043,000	3,500,000	1,109,000	9,595,000	21,697,000	-1,385,000
cash and cash equivalents at beginning of period	0	0	0	0	0	0	0	0		0	0	13,001,000
cash and cash equivalents at end of period	7,685,000	20,388,000	4,043,000	3,500,000	1,109,000	9,595,000	21,697,000	-1,385,000		-1,346,000	944,000	10,154,000
supplemental cash flow information
interest paid										265,000	10,923,000	364,000
income taxes paid										623,000	1,055,000	1,136,000
non-cash investing and financing activities
property, plant and equipment
foreign currency losses
stock-based compensation expense
changes in operating assets and liabilities, net of business acquisition
proceeds from insurance premium financing
payments of insurance premium financing
changes in operating assets and liabilities
net decrease in cash and cash equivalents
foreign currency (gains) losses						-3,216,000	-1,609,000	652,000
net cash (used) provided by financing activities		1,787,000
gain on sale of investment
sale of investment				0
payment of contingent consideration				0
net cash provided (used) by operating activities:
net cash provided (used) by operating activities								10,109,000
acquisition-related cost of goods sold								0
changes in operating assets and liabilities:
net cash from financing activities
foreign currency gains			-5,374,000
business acquisition								0
net cash (used) provided by operating activities:
net cash (used) provided by operating activities
cash proceeds from the sale of investment
net cash from investing activities
(gain) on sale of investment				0
foreign currency (gains)				8,684,000
changes in operating assets and liabilities, net of business acquisitions:
business acquisitions						0	0
payments of long-term debt and other				-3,750,000	-206,562,000	-3,160,000
property, plant and equipment and capital lease additions
net cash used by financing activities
issuance of acquisition note payable							0
payment of acquisition note payable							0
proceeds from common shares issued							0	407,000
net cash (used) by investing activities
adjustments to reconcile net income to net cash provided (used) by operating activities:
proceeds from common stock issued
amortization of debt issuance costs and debt discount							220,000	221,000
acquisition-related costs of goods sold
acquisition-related accrued interest								290,000
net cash provided (used) by investing activities								-10,021,000
loss on extinguishment of debt
payments of long-term debt, capital leases and other							-3,145,000	-1,582,000
acquisition-related accrued compensation								68,000
acquisition-related other
amortization of deferred financing costs and debt discount
payment of premiums and costs on extinguished debt
accrued interest
deferred income taxes valuation allowance
prepaid expenses and other current assets
borrowings under the revolving credit facility
repayments of the revolving credit facility
acquisition related accrued compensation
acquisition related accrued interest
borrowings under the revolving and domestic senior credit facility
repayments of the revolving and domestic senior credit facility
capital / leasehold improvements and capital lease additions
borrowings under the domestic senior and revolving credit facility
repayments of the domestic senior and revolving credit facility
proceeds from new common shares issued
capital/leasehold improvements
capital lease additions										5,000
net										-1,359,000	-2,015,000	-2,791,000
adjustment for discontinued operations
(loss) from continuing operations										-1,359,000	-2,015,000	-2,791,000
adjustments to reconcile (loss) from continuing operations to net cash provided (used) by operating activities:
cash provided (used) by discontinued operations
proceeds from belgium plant transactions										0
proceeds from sales of assets										1,697,000	-501,000	738,000
other investing
discontinued operations
net increase in book overdrafts
payments of long-term debt and capital leases										-785,000
proceeds from capital contribution by pahc holdings corporation
redemption of series c preferred stock
debt financing costs
operating activities:
amortization of deferred financing costs
net gain from sales of assets
effects of changes in foreign currency
accrued costs of non-completed transaction
accrued costs of the belgium plant transactions
investing activities:
financing activities:
net increase in cash overdraft											1,410,000	223,000
net (decrease) in short-term debt
supplemental cash flow information:
adjustments to reconcile (loss) from continuing operations to net cash from operating activities:
net increase in short-term debt												-3,713,000
income from continuing operations
adjustments to reconcile income from continuing operations to net cash provided (used) by operating activities:
payment of pfizer obligations
payments relating to the prince transactions and related costs

We provide you with 20 years of cash flow statements for Phibro Animal Health stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Phibro Animal Health stock. Explore the full financial landscape of Phibro Animal Health stock with our expertly curated income statements.

The information provided in this report about Phibro Animal Health stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.